Daiichi Sankyo Announces Large-scale Registry of Venous Thromboembolism (VTE) in Cancer Patients

Daiichi Sankyo press release ------- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has commenced a company-initiated large-scale clinical registry for cancer patients (hereafter, Cancer-VTE Registry). The Cancer-VTE Registry is an observational study that will enroll and follow up to 10,000 cancer patients for one year for the following purposes: Identify the frequency of concurrent VTE in registered patients and clarify the background factors of patients with VTE complications. Identify treatment status of VTE in registered patients. Investigate the incidence of VTE events, hemorrhagic events, ischemic stroke and systemic embolisms at the time of observation in a registered patient for one year, and clarify background factors related to the events to understand the optimal group to be treated for Direct Oral Anticoagulant (DOAC) and clarify appropriate use of DOAC including LIXIANA® (Edoxaban Tosilate Hydrate, hereafter Edoxaban) for that group. To get more in depth information click on the picture below to read the release.